Meridian Bioscience, Inc. (NASDAQ:VIVO) shareholders are probably feeling a little disappointed, since its shares fell 6.0% to US$18.51 in the week after its latest quarterly results. It looks to have ...

It happened to diagnostic test maker Meridian Bioscience Inc. (NASDAQ:VIVO), but at least it doesn’t appear to have caused any damage. Meridian was victimized by a Twitter “name squatter.” That is, ...

Here at The Motley Fool, I've long cautioned investors to keep a close eye on inventory levels. It's a part of my standard diligence when searching for the market's best stocks. I think a quarterly ...

Most readers would already be aware that Meridian Bioscience's (NASDAQ:VIVO) stock increased significantly by 9.0% over the past month. Given the company's impressive performance, we decided to study ...

In light of its acquisition by South Korea's SD Biosensor and SJL Partners for $1.53B, William Blair has downgraded Meridian Bioscience (NASDAQ:VIVO) to market perform. The consortium first made ...

Cincinnati, Ohio life sciences company Meridian Bioscience Inc. (NASDAQ: VIVO) has acquired the outstanding capital stock of Bioline Ltd., the London, England-based maker and distributor of molecular ...

New formats redefine molecular assay development by cutting refrigeration costs, simplifying logistics, and ensuring uncompromised performance at room temperature. For decades, the molecular ...

New CEO, CFO, and EVP of Life Science named to drive strategic execution across Diagnostics and Life Science. CINCINNATI, Oct. 14, 2025 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global ...

For the quarter ended Dec. 31 (Q1), Meridian Bioscience missed on revenues and whiffed on earnings per share. Compared to the prior-year quarter, revenue grew and earnings per share grew. Gross ...

Don't just count the cash, time it. It takes money to make money. Most investors know that, but with business media so focused on the "how much," very few investors bother to ask, "How fast?" When ...